Idera's IMO-3100 misses Phase IIa psoriasis endpoint

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) said once-weekly subcutaneous IMO-3100 for four weeks with a four week follow-up period missed the primary endpoint in a Phase IIa trial to treat moderate to s...